- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma Gets CDSCO Panel Nod To Market Sitagliptin, Metformin, Glimepiride FDC in Lower Strength
New Delhi: Pharmaceutical major Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market the fixed-dose combination antidiabetic drug Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg/50mg plus Metformin Hydrochloride IP 500mg/500mg plus Glimepiride IP 1mg/2mg film-coated tablet.
This came after the drug major Sun Pharma presented their proposal for a bioequivalence (BE) study and Phase III clinical trial wavier for lower strength i.e. Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg/50mg plus Metformin Hydrochloride IP 500mg/500mg plus Glimepiride IP 1mg/2mg film-coated tablet based on Phase III clinical trial and BE study results presented for higher strength i.e. Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg/50mg plus Metformin Hydrochloride IP 1000mg/1000mg plus Glimepiride IP 1mg/2mg film-coated tablet.
Sitagliptin phosphate monohydrate is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Sitagliptin phosphate works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). Sitagliptin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
Metformin is an oral anti-diabetic drug in the biguanide class for the treatment of type 2 diabetes mellitus, in particular, in overweight and obese people and those with normal kidney function. Metformin is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes. With this type of diabetes, insulin produced by the pancreas is not able to get sugar into the cells of the body where it can work properly.
Glimepiride is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the sulfonylurea class of drugs. Glimepiride is used to treat high blood sugar levels caused by type 2 diabetes. It may be used alone or in combination with insulin or another oral medicine such as metformin. In type 2 diabetes, insulin produced by the pancreas is not able to get sugar into the cells of the body where it can work properly.
At the recent SEC meeting for Endocrinology and Metabolism held on 19th September 2023, the expert panel reviewed the proposal presented by the drug major Sun Pharma for BE study and Phase III clinical trial waiver for the lower strength of the FDC Antidiabetic Drug Sitagliptin Phosphate Monohydrate plus Metformin Hydrochloride plus Glimepiride film-coated tablet along with the BE study report for the higher strength i.e. Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg/50mg plus Metformin Hydrochloride IP 1000mg/1000mg plus Glimepiride IP 1mg/2mg film-coated tablet.
After detailed deliberation, the committee recommended the grant of permission to manufacture and market the product in the lower strength.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.